Fujifilm To Invest $200 Mn To Open 100 Health-screening Centres In India

Fujifilm on Thursday said it plans to invest around USD 200 million (about Rs 1,450 crore) to open 100 health-screening centres in India to test 10 common cancers.

Fujifilm andDr Kutty's Healthcare on Thursday launched the first of these 'NURA centres', equipped with artificial intelligence (AI) enabled imaging and expert healthcare in Bengaluru, the companies said in a statement.

The centre can correctly test 10 common cancers -- oral cancer, breast cancer, cervical cancer, lung cancer, stomach cancer, colon cancer, prostate cancer, esophageal cancer, laryngeal cancer and early signs of leukemia along with other lifestyle diseases.

Masaharu Morita, global marketing and new business manager, Modality Solution, Medical Div, Fujifilm said: "In the coming years, we plan to invest around USD 200 Mn to set up 100 such NURA centres across the country."

With NURA, "our vision is to introduce the culture of periodic health screening in India, as we believe that early detection and treatment are very important to improve the survival rate of cancer patients," he added.

"Together with Dr Kutty's Healthcare expertise, we will continue to support the development of medical care by providing state-of-the-art products and services that contribute to improved health and quality of life of people worldwide," Morita said.

Dr Kutty's HealthcarePresidentMohamed Kasim said, "We are committed to providing sustained health through NURA by leveraging our experience in healthcare and high-quality scanning and image processing technology offered by Fujifilm."

In addition to 10 cancer tests, the centres will provide total medical examination services such as early detection of risks of metabolic syndrome and locomotive syndrome, for the examination of lifestyle-related diseases such as chronic obstructive pulmonary disease and myocardial infarction, Fujifilm said.

The health screening centres will actively leverage intelligent AI-technology to improve outcomes for both the patient and the doctor by making the screening process safe and more accurate, it added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor